Life Sciences startup ecosystem
We track 57 organisations in this sector across 6+ countries.
Showing 21–40 of 57Life Sciences
Countries in this sector
Sectors alongside this one
Life Sciences results
Infineis
Nice medical device company developing precise guidance systems for intracranial interventions, with a second presence in Sherbrooke, Canada. It builds customised devices and therapeutic delivery platforms for neurosurgery spanning clinical use, preclinical and clinical pharmaceutical research, and veterinary neurosurgery. Infineis is an alumnus of the MonacoTech incubator.
Innogest Capital
Founded in 2007, Innogest Capital is a Milan-based early-stage VC, with offices in Turin, Geneva and San Francisco, managing over EUR 150M across funds focused on technology and life sciences. The firm invests EUR 0.5-5M at Series A in digital platforms, IoT, healthcare, and industrial tech. Notable portfolio companies include Genenta Science (IPO on Nasdaq), Musement (acquired by TUI), and Pharmacell. Innogest is one of Italy's pioneer independent VC firms with deep networks in the Piedmont and Lombardy tech ecosystems.
IST cube
IST cube is an early-stage, deep-tech venture capital firm and incubator connected to the Institute of Science and Technology Austria (ISTA) near Vienna. It invests seed capital in science-based startups, particularly in artificial intelligence, life sciences and other frontier technologies, and supports founders spinning research out of academia into companies.
Jessica Martinsson
Jessica Martinsson is Director General and CEO of SwedenBIO, Sweden's national trade association for the life science sector representing biotech, pharmaceutical, and medtech companies. She leads the organization that owns and produces Nordic Life Science Days, the largest partnering event in the Nordic life science industry. She advocates for Swedish life science competitiveness and innovation policy at national and EU levels.
Kevin Dalgaard
Kevin Dalgaard is Senior Principal at Lundbeckfonden BioCapital, the venture capital investment arm of the Lundbeck Foundation, one of Denmark's largest private foundations dedicated to advancing research in brain and neurological diseases. He evaluates and manages life science investments across the Nordic and global biotech ecosystems. Lundbeckfonden BioCapital is a key and highly respected institutional investor in the Scandinavian life science community.
Kristina Ekberg
Kristina Ekberg is Partner at HealthCap, one of Europe's largest dedicated life science venture capital firms, headquartered in Stockholm, Sweden. She focuses on biotech and pharmaceutical investments in the Nordic region and beyond. HealthCap has been one of the most active life science investors in Scandinavia for more than two decades, managing multiple funds with a strong track record of exits.
Layla Hosseini-Gerami
Scientist and entrepreneur working at the intersection of AI and drug discovery, focused on using computational methods to rescue and repurpose previously failed drug candidates. She is an announced speaker at the 2026 TEDAI Vienna conference on AI and drug discovery.
Maha Radhakrishnan
Maha Radhakrishnan, MD, is Executive Partner at Sofinnova Investments, one of Europe's leading dedicated life science venture capital firms. A physician-scientist by training, she brings deep expertise in biopharmaceuticals and drug development to evaluating and supporting therapeutic companies across oncology, rare diseases, and CNS disorders. She is a prominent investor and speaker in the European and global biotech ecosystem.
Malta Life Sciences Park
Malta Life Sciences Park (MLSP) is a 13,500 sqm facility in San Gwann providing laboratories, offices, meeting rooms, and shared infrastructure to life sciences, biotechnology, and healthcare IT companies at all stages from startup to established enterprise. Built with EU regional development funds and opened in 2015, it serves as the national focal point for R&D in the life sciences sector and is co-located near the University of Malta and the main government hospital.
Malta Venture Capital (MVC)
Malta Venture Capital (MVC) is a €10 million government-backed equity fund launched in 2024 and managed from offices in Sliema, under the auspices of Malta Government Investments. It co-invests alongside private investors in early-stage, high-growth digital and technology-driven businesses, with each eligible startup able to receive up to €500,000 in equity. Target sectors include video game development, fintech, e-sports, life sciences, agritech, AI, and green energy. Since launch MVC has invested in five companies and assembled a network of 30 accredited co-investors.
Niklas Blomberg
Niklas Blomberg is Executive Director of the Innovative Health Initiative (IHI), a major public-private partnership joint undertaking established by the European Union and EFPIA with approximately €2 billion in funding for health research and innovation. He oversees one of Europe's most significant health R&D programmes, bridging academia, industry, regulators, and patient organisations. He is a key figure in European health innovation policy and ecosystem building.
Norway Health Tech
Norway Health Tech is Norway's largest and leading health technology cluster, bringing together more than 350 member organizations including companies, investors, healthcare providers, municipalities, and research institutions. Founded to drive growth in the health industry and accelerate innovation, the organization operates offices in Oslo, Bergen, and Stavanger. It organizes the annual Healthtech Festival series held across Norway and runs major public-private partnership initiatives such as Health2B at Oslo Science Park and the Nordic Health Connect project. The cluster also leads efforts in health technology for defence and emergency preparedness.
NovaUCD
NovaUCD is the innovation and startup incubator of University College Dublin (UCD), one of Ireland’s premier research universities. Established in 2003 on UCD’s Belfield campus, NovaUCD provides a supportive environment for knowledge-intensive startups, particularly those arising from university research in life sciences, engineering, and ICT. The center offers modern incubation facilities, including lab space, prototype workshops, and offices set in a historic Georgian building refurbished for innovation. NovaUCD runs a 9-month VentureLaunch accelerator program to help researchers and students validate business ideas, build teams, and refine commercialization strategy. Startups benefit from UCD’s resources – access to faculty experts, graduate talent, and sometimes use of specialized equipment (for biotech, etc.). Over nearly two decades, NovaUCD has supported 450+ companies. Alumni include Evolution (Bio) – a UCD bioinformatics spin-out acquired by Evotec, Logentries (cloud logging, acquired by Rapid7 for $68M), and Equinome (equine genomics, acquired by Plusvital). These successes underscore NovaUCD’s strength in turning academic excellence into enterprise. A hallmark is its focus on knowledge transfer: NovaUCD works closely with UCD’s tech transfer office, so startups often license university patents or software as a basis. The incubator also facilitates seed funding through networks like Halo Business Angel Network (HBAN) and University Bridge Fund (a college-focused VC). The Irish government and Enterprise Ireland are key backers, aligning NovaUCD with national goals to foster high-tech industry. The incubator has expanded physically too – in 2022, it opened “AgTech UCD” on UCD’s Lyons farm for agri-tech startups, reflecting an effort to specialize. NovaUCD contributes hugely to Dublin’s startup scene, connecting academic founders with industry mentors and investors. Each year it hosts the UCD VentureLaunch Competition awarding cash prizes to the most promising spin-outs. Notably, NovaUCD companies have raised over €760M in capital and created thousands of jobs in Ireland. By offering an “on-campus home” for entrepreneurs, NovaUCD helps ensure that Ireland’s top research doesn’t just stay on paper, but translates into impactful businesses – from lifesaving medical devices to groundbreaking software – driving innovation and economic growth.
Novetech Surgery
Nice-based medical device company on Boulevard du Tzarewitch that designs, manufactures and distributes minimally invasive orthopaedic implants for veterinary surgery. Its range covers synthetic ligament and tendon reconstruction, bone surgery and visceral implants, alongside professional training for veterinary surgeons. The company is an alumnus of the MonacoTech incubator across the nearby border.
PFR Ventures
PFR Ventures is the venture capital arm of the Polish Development Fund (Polski Fundusz Rozwoju), wholly owned by the Polish state, established in 2014 and based in Warsaw. The firm operates as the largest fund-of-funds manager in the Central and Eastern Europe region, managing over PLN 3 billion in assets across 80+ private VC funds that have collectively supported more than 900 startup investments. PFR Ventures co-invests alongside private LPs to leverage EU structural funds and catalyse private capital into the Polish venture ecosystem, backing early-stage through growth-stage funds in sectors including deep tech, SaaS, fintech, and life sciences. Its Innovate Poland programme launched in November 2025 with at least PLN 4 billion earmarked for the next investment cycle.
Pharmacelera
Pharmacelera is a Barcelona-based computational drug discovery company headquartered at the Parc Cientific de Barcelona, combining computer-aided drug design, AI and machine learning, and high-performance computing to explore larger and more diverse chemical space. Its software suite, including PharmScreen, exaScreen, and PharmQSAR, helps pharma and biotech companies with target identification, hit identification, hit-to-lead, and lead optimization by finding novel hits and improving ligand binding properties. Clients referenced on its site include Sanifit Laboratoris and Wren Therapeutics.
PORT for Health: Oncology 2026
International healthtech and biotech conference hosted by Łukasiewicz – PORT, focused on cancer research, diagnostics, and therapy. Relevant for healthtech and biotech founders and researchers seeking R&D partners, clinical collaborators, and exposure to the Łukasiewicz innovation network.
ScanBalt
ScanBalt (ScanBalt MTÜ) is a network organization founded around 2001 and headquartered in Tartu, Estonia, whose mission is to develop the Baltic Sea Region as a single test site for healthcare products and services across life sciences, health data, and precision medicine. Celebrating its 25th anniversary in 2026, ScanBalt serves as co-organizer of the Estonian HealthTech Week and connects innovators, researchers, and policymakers across the Nordic and Baltic countries.
ScandiBio Therapeutics
ScandiBio Therapeutics is a Stockholm-based pharmaceutical company developing AI-driven drugs that target mitochondrial dysfunction, a factor implicated in neurodegenerative disorders and metabolic syndromes. Its lead product has entered a randomized, double-blind, placebo-controlled Phase III clinical trial in Turkey for patients with mild, moderate, and severe Alzheimer's disease, and has also completed Phase II trials in fatty liver patients and Phase III trials in COVID-19 patients. The company was founded by scientists affiliated with KTH Royal Institute of Technology, Karolinska Institutet, Sahlgrenska University Hospital, and King's College London.
Sibylla Biotech
Sibylla Biotech is a preclinical-stage Italian biotech developing small-molecule protein degraders through a proprietary technology it calls Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT), powered by computer simulations and AI on its Oneiros platform. The company is a spin-off of INFN, the University of Trento, and the University of Perugia, co-founded by Emiliano Biasini and Pietro Faccioli. Sibylla has signed drug discovery collaborations with Takeda and Ono Pharmaceutical and raised a EUR 23 million Series A round in 2022 to advance its internal pipeline and expand its technology platform.
